An interdisciplinary pharmacoeconomic study of pharmacotherapy for the relief of alcoholic dependence on the basis of experimental clinical and pharmacological, organizational, legal and marketing studies. The scheme of basic pharmacotherapy of relief of drunken forms of alcohol dependence developed by the authors for the interdisciplinary study was used. Thirteen international nonproprietary names of drugs from Ukrainian (92.3%) and foreign (7.7%) manufacturers were selected. It was established that for pharmacotherapy of support of relief of drunken forms of alcohol dependence tablets occupy 23,1% of appointments of doctors, solutions – 76,9%. The scheme of pharmacotherapy in the relief of intoxicated forms of alcohol dependence includes 38.5% of international nonproprietary names of drugs with ATC code "A" - drugs that affect the digestive system and metabolism; 30.7% with ATC code "B" - drugs that affect the blood system and hematopoiesis; 15.4% with ATC codes of classification "C" – drugs that affect the cardiovascular system and "N" – drugs that affect the nervous system. Nomenclature and legal analysis showed that 92.3% of the studied drugs belong to prescription nomenclature and legal group; the share of OTC drugs is 7.69% (international nonproprietary name Antral).
18 January 2022 in SSP Modern Pharmacy and Medicine
An integrated ABC/VEN analysis of drug prescriptions in pharmacotherapeutic schemes for the relief of alcoholic dependence was performed. A retrospective analysis of seventy-five anonymized case histories of patients who sought medical help with drunken forms of alcoholic dependence was processed. The scheme of basic pharmacotherapy of relief of drunken forms of alcoholic dependence, developed by associate professor Yurii Chuiev for carrying out interdisciplinary study was used. Substantiated that the introduction of the developed innovative treatment algorithm, with the use of laser therapy, infusion therapy, anticonvulsants and hepatoprotectors allowed to create an effective treatment complex to alleviate this drug pathology. Pharmacoeconomic research was based on organizational and legal, clinical and pharmacological standards. Dosage forms of drugs according to medicinal purposes have been established in pharmacotherapeutic regimens for the relief of drunken forms of alcoholic dependence (tablets occupy 23.1% of appointments, solutions – 76.9%). The results of ABC analysis were given. Category A included seven INNs of drugs, the share of which was 81.13% of the total cost of pharmacotherapy of alcoholic dependence. Category B included four INNs of drugs with a cost share of 15.07%. In the category of C – two INNs of drugs with a share of costs of 4.80% for pharmacotherapy of relief of drunken states of alcoholic dependence. Overall, 85% of the studied drugs were included in pharmacotherapy as Vital, 15% as Essential. The results of the study can be used in conducting of budget tenders for the purchase of drugs, the rational use of drugs, the inclusion of drugs in regional and local forms for pharmacotherapy for the relief of drunken forms of drugs in healthcare facilities.
The article highlights the current recommendations of the World Health Organization (WHO) on the optimization of antidepressant programs. Based on global WHO studies conducted in 36 countries with different income levels, it is proven that the low level of recognition and treatment of depression and anxiety disorders leads to significant socio-economic losses. Particular attention is paid to losses for households, employers, and states, as well as insufficient financing of mental health even in high-income countries. The economic feasibility of investments in mental health is substantiated, through treatment that includes psychotherapy, drug therapy or their combination with the support of WHO mhGAP recommendations. The relationship of depression with other non-communicable diseases and the risk of suicidal behavior is separately considered. In a practical context, cases of depressive disorders among workers are analyzed, in conditions of military operations, economic instability and substance abuse. The importance of compliance with labor legislation in the context of mental health protection is described. A clinical approach to the complex therapy of depression of alcoholic origin in the post-abstinence period with the use of trazodone and cocarnitine is proposed, which demonstrates effectiveness in overcoming pathological craving for alcohol and stabilizing the psycho-emotional state. The results of the study indicate the feasibility of long-term active and supportive therapy to prevent relapses.
During the circulation of drugs within the multidisciplinary organizational and legal, forensic and pharmaceutical, medical and immunological researches in the organization and management of pharmaceutical competencies, a comparative analysis of the cost of pharmacotherapy in the relief of alcoholism to determine the most cost-effective treatment regimen. Two modern schemes of pharmacotherapy for relief of drunken forms of alcohol dependence were developed. During the circulation of medicines, eleven drugs were selected for the main group and ten drugs for the control group. Organized a comparative analysis of the cost of basic pharmacotherapy in the relief of alcoholic dependence to determine the most cost-effective treatment regimen. Found that the cost of the basic pharmacotherapy scheme for the experimental group of patients is 40% cheaper than the basic pharmacotherapy scheme for the control group. It was established that the scheme of the course of pharmacotherapy in the relief of alcoholic addictions for the research group is more effective, safer, economical and has fewer side effects on the patient's body.
1 January 2026 in SSP Modern Pharmacy and Medicine
The COVID-19 pandemic prompted the development of innovative approaches to the treatment of severe forms of pneumonia with pneumo-pleurofibrosis. An IV regimen based on intravenous administration of ethyl alcohol solutions of different concentrations with glucose in patients with COVID-19 (intervention group and control groups of comparable number) was proposed and clinically evaluated. The use of 10% Ethanol has been introduced: 150 ml intravenously drip 2 times a day for 7 days. In both groups, hyperthermia, tachypnea, dry cough, pleural pain, diffuse cyanosis, severe general condition, a significant decrease in oxygen saturation, leukocytosis and lymphopenia were found at the beginning of treatment. In the intervention group, the normalization of indicators occurred much faster: body temperature returned to normal on the fifth to seventh day versus the twelfth-fourteenth in the control; respiratory rate – on the fourth to fifth day versus the sixteenth to eighteenth; saturation reached normal on the sixth to eighth day against the twelfth-fifteenth; leukocytes returned to normal on the tenth to eleventh day against the sixteenth to eighteenth; Lymphocytes stabilized on the sixth to eighth day versus the twentieth to twenty-second. On the seventh day, a satisfactory condition was observed in most patients in the intervention group without deaths, in the control - much later and in smaller numbers. The technique of using intravenous ethanol is based on the classical principles of detoxification therapy: elimination of the toxic factor with subsequent elimination of the consequences of intoxication, which provides an etiotropic-pathogenetic effect in acute vasculitis and pneumo-pleurofibrosis. The proposed scheme reduces the duration of treatment, reduces costs, and requires further clinical, pharmacological and pharmacoeconomic studies.
1 October 2025 in SSP Modern Pharmacy and Medicine
The article presents the results of a clinical and pharmacological study of the efficacy, tolerability, and safety of complex therapy of depressive disorders in patients with alcohol dependence. The aim of the study was to increase the effectiveness of treatment of comorbid depressive states by combining pharmacotherapy with the antidepressant escitalopram (Cipralex) with the use of intravascular laser hemotherapy and laser reflexology. The study included 50 men of working age, distributed into two groups: the main one (30 people) who received combination therapy, and the control group (20 people) who underwent monotherapy with Cipralex. Effectiveness was assessed using standardized psychometric scales (Hamilton, Montgomery-Asberg scale, Spielberger-Hanin, asthenic scale, quality of life scale). The results showed that patients in the main group experienced a more rapid reduction in depressive symptoms, a decrease in anxiety and asthenia, as well as a significant improvement in quality of life compared to the control group. The therapeutic effects of laser methods contributed to increasing the psycho-emotional stability, performance, and social adaptation of patients, which confirms the expediency of including laser therapy in the treatment programs for alcoholic depression. No side effects or cases of intolerance have been reported. The proposed integrated approach of combining pharmacotherapy with antidepressants with laser methods can be recommended for interdisciplinary treatment and rehabilitation programs to restore mental health and return to productive activities of able-bodied citizens.